Media Summary: HealthWatch: Signatera – Personalized Blood Test Detects Watch the video to learn more about how we're pairing a genetic risk assessment with your routine screenings, and what you can ... Founder Matthew Rabinowitz opens up about the intensely personal journey that set him on a course to revolutionizing healthcare ...

Natera Ceo On Cancer Recurrence Detection And How It Works - Detailed Analysis & Overview

HealthWatch: Signatera – Personalized Blood Test Detects Watch the video to learn more about how we're pairing a genetic risk assessment with your routine screenings, and what you can ... Founder Matthew Rabinowitz opens up about the intensely personal journey that set him on a course to revolutionizing healthcare ... This presentation examines IL-15's role in urological The emergence of treatments targeting KRAS, which is the driving force of growth for most pancreatic

Photo Gallery

Natera CEO on cancer recurrence detection and how it works
Natera CEO: We’re using DNA tech to change disease management
Natera Oncology
Natera: Managing Disease Via Genetic Sequencing
Natera CEO Steve Chapman at Nasdaq
Harnessing cell-free DNA testing to combat transplant rejection | Natera
The Signatera Approach
Is the cancer coming back? Using Signatera to detect molecular residual disease (MRD)
Exhibitor Showcase: Natera
HealthWatch: Signatera – Personalized Blood Test Detects Cancer Recurrence
Technology helps detect recurrence of cancer through a blood test
A ctDNA assay for remote monitoring and risk stratification
Sponsored
Sponsored
View Detailed Profile
Natera CEO on cancer recurrence detection and how it works

Natera CEO on cancer recurrence detection and how it works

Steve Chapman,

Natera CEO: We’re using DNA tech to change disease management

Natera CEO: We’re using DNA tech to change disease management

Jim Cramer chats with

Sponsored
Natera Oncology

Natera Oncology

Natera

Natera: Managing Disease Via Genetic Sequencing

Natera: Managing Disease Via Genetic Sequencing

July 2 -- Matthew Rabinowitz,

Natera CEO Steve Chapman at Nasdaq

Natera CEO Steve Chapman at Nasdaq

Natera CEO

Sponsored
Harnessing cell-free DNA testing to combat transplant rejection | Natera

Harnessing cell-free DNA testing to combat transplant rejection | Natera

Prospera, developed by

The Signatera Approach

The Signatera Approach

The Signatera Approach

Is the cancer coming back? Using Signatera to detect molecular residual disease (MRD)

Is the cancer coming back? Using Signatera to detect molecular residual disease (MRD)

Is the

Exhibitor Showcase: Natera

Exhibitor Showcase: Natera

Exhibitor Showcase:

HealthWatch: Signatera – Personalized Blood Test Detects Cancer Recurrence

HealthWatch: Signatera – Personalized Blood Test Detects Cancer Recurrence

HealthWatch: Signatera – Personalized Blood Test Detects

Technology helps detect recurrence of cancer through a blood test

Technology helps detect recurrence of cancer through a blood test

Natera CEO

A ctDNA assay for remote monitoring and risk stratification

A ctDNA assay for remote monitoring and risk stratification

Presented Alexey Aleshin,

Natera Empower | AdventHealth

Natera Empower | AdventHealth

Watch the video to learn more about how we're pairing a genetic risk assessment with your routine screenings, and what you can ...

Natera Signatera Product Theater at SABCS 2022: The Cycle of ctDNA

Natera Signatera Product Theater at SABCS 2022: The Cycle of ctDNA

Course with primary breast

Natera ft. Matthew Rabinowitz - A Personal Mission That Led to a Biotech Revolution

Natera ft. Matthew Rabinowitz - A Personal Mission That Led to a Biotech Revolution

Founder Matthew Rabinowitz opens up about the intensely personal journey that set him on a course to revolutionizing healthcare ...

A ctDNA assay for remote monitoring and risk stratification of CRC patients

A ctDNA assay for remote monitoring and risk stratification of CRC patients

Presenters: Abigail Smith, CRNP, MSN.

Immunity Bio: AUA Cancer Lecture with Dr. Patrick Soon-Shiong

Immunity Bio: AUA Cancer Lecture with Dr. Patrick Soon-Shiong

This presentation examines IL-15's role in urological

Tal Danino: We can use bacteria to detect cancer (and maybe treat it)

Tal Danino: We can use bacteria to detect cancer (and maybe treat it)

Liver

NATERA GALAXY Study Links ctDNA Status to Survival & Treatment Response ESMO 2024

NATERA GALAXY Study Links ctDNA Status to Survival & Treatment Response ESMO 2024

Download Slides: https://oncologytube.com/

Dr. Borazanci shares important insights on the latest advances in KRAS-targeted therapies.

Dr. Borazanci shares important insights on the latest advances in KRAS-targeted therapies.

The emergence of treatments targeting KRAS, which is the driving force of growth for most pancreatic